Latest Content

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Giredestrant improved invasive disease-free survival for people with estrogen receptor-positive early breast cancer compared with standard treatment.

I share how the nurses who cared for my daughter during chemotherapy brought comfort, connection and humanity that carried us through our hardest moments.

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.

Dr. Anne Chiang explains how biomarker testing and molecular profiling personalize lung cancer treatment and compare tissue versus liquid biopsies.

Dr. Ajay Gupta sat down with CURE to explain the basics of gastrointestinal stromal tumors, highlighting what patients with this disease need to know.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

I reflect on my brain tumor journey, sharing how gratitude, love and connection with my parents and others strengthened me through difficult times.